Oxcarbazepine (All indications) updated on 04-22-2025

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16069
R66686		 Christensen (Oxcarbazepine) (All indications) (Controls exposed to LTG), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.52 [1.30;1.77] C
excluded (control group) 		241/1,591   920/8,756 1,161 1,591
ref
S16028
R66534		 Christensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.48 [1.28;1.71] 241/1,591   446,267/4,467,848 446,508 1,591
ref
S9039
R30840		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 7.80 [0.23;262.83] C
excluded (control group) 		1/4   0/7 1 4
ref
S9040
R30850		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 25.80 [0.81;819.45] C 1/4   0/22 1 4
ref
S9087
R31113		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Small for gestational age (weight) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.00 [0.58;1.74] C 14/143   167,376/1,710,441 167,390 143
ref
S9041
R30861		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.43 [0.99;2.07]
excluded (control group) 		47/1,109   106/2,682 153 1,109
ref
S9043
R30875		 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.95 [0.70;1.27] 47/1,109   41,653/1,440,631 41,700 1,109
ref
S9042
R30866		 Bank (Oxcarbazepine) (Mixed indications), 2017 Small for Gestational Age birthweight (<10th percentile) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 3.67 [0.29;47.11] C 1/4   3/36 4 4
ref
Total 5 studies 1.23 [0.85;1.77] 655,603 2,851
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 1.48[1.28; 1.71]446,5081,59141%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 2 25.80[0.81; 819.45]141%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 3 1.00[0.58; 1.74]167,39014322%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019Cohen, 2019 4 0.95[0.70; 1.27]41,7001,10934%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Bank (Oxcarbazepine) (Mixed indications), 2017Bank, 2017 5 3.67[0.29; 47.11]442%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 65% 1.23[0.85; 1.77]655,6032,8510.2100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (All indications) (Controls unexposed, general population; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine) (Controls unexposed, NOS; 4: Oxcarbazepine) (Controls unexposed NOS) (Mixed indications; 5: Oxcarbazepine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.23[0.85; 1.77]655,6032,85165%NAChristensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Bank (Oxcarbazepine) (Mixed indications), 2017 5 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.17[0.82; 1.65]655,5982,84375%NAChristensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 3 unexposed, sickunexposed, sick 25.80[0.81; 819.45]14 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 3.67[0.29; 47.11]44 -NABank (Oxcarbazepine) (Mixed indications), 2017 1 Tags Adjustment   - No  - No 2.45[0.45; 13.43]167,39515152%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Bank (Oxcarbazepine) (Mixed indications), 2017 3   - Yes  - Yes 1.21[0.78; 1.86]488,2082,70085%NAChristensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 2 All studiesAll studies 1.23[0.85; 1.77]655,6032,85165%NAChristensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Bank (Oxcarbazepine) (Mixed indications), 2017 50.2100.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.14.42.1170.000Christensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019Bank (Oxcarbazepine) (Mixed indications), 2017

Asymetry test p-value = 0.9097 (by Egger's regression)

slope=0.2814 (0.1814); intercept=0.1550 (1.2570); t=0.1233; p=0.9097

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9041, 9039, 16069

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.17[0.82; 1.65]655,5982,84375%NAChristensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 3 unexposed, sick controlsunexposed, sick controls Out of scale25.80[0.81; 819.45]14 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.51[1.32; 1.74]1,3192,7080%NAChristensen (Oxcarbazepine) (All indications) (Controls exposed to LTG), 2024 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Bank (Oxcarbazepine) (Mixed indications), 2017 40.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (All indications) (Prenatal ...Veroniki a (NMA) (All indications) (Prenatal growth restriction) 0.99[0.56; 1.76]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.23[0.85; 1.77]65%2,851----Christensen (Oxcarbazepine) (All indications) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Bank (Oxcarbazepine) (Mixed indications), 2017 50.510.01.0